Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions
暂无分享,去创建一个
Kai Shu | F. Ye | H. Nakashima | R. Piranlioglu | Junfeng Liu | T. Lei | Junfeng Liu
[1] H. Kaufman,et al. Therapy with oncolytic viruses: progress and challenges , 2023, Nature Reviews Clinical Oncology.
[2] K. Azadmanesh,et al. Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand? , 2022, Cancer Cell International.
[3] M. Boldrini,et al. Spatial profiling of chromatin accessibility in mouse and human tissues , 2022, Nature.
[4] T. Todo,et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial , 2022, Nature Medicine.
[5] J. Christie,et al. Treat and repeat: oncolytic virus therapy for brain cancer , 2022, Nature Medicine.
[6] G. Dharmadhikari,et al. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. , 2022, The New England journal of medicine.
[7] Maohui Luo,et al. A map of the spatial distribution and tumour‐associated macrophage states in glioblastoma and grade 4 IDH‐mutant astrocytoma , 2022, The Journal of pathology.
[8] A. Desjardins,et al. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice , 2022, Neurotherapeutics.
[9] Binzhi Qian,et al. Macrophage diversity in cancer revisited in the era of single-cell omics. , 2022, Trends in immunology.
[10] J. Hossain,et al. Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities , 2022, Cancers.
[11] Maohui Luo,et al. Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model , 2022, Virology Journal.
[12] G. Castelo-Branco,et al. Spatial-CUT&Tag: Spatially resolved chromatin modification profiling at the cellular level , 2022, Science.
[13] A. Planas,et al. Protein Expression of the Microglial Marker Tmem119 Decreases in Association With Morphological Changes and Location in a Mouse Model of Traumatic Brain Injury , 2022, Frontiers in Cellular Neuroscience.
[14] E. Chiocca,et al. Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword , 2022, International journal of molecular sciences.
[15] Zhongming Zhao,et al. NOTCH induced MDSC recruitment after oHSV virotherapy in CNS cancer models modulates anti-tumor immunotherapy. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] J. Gumin,et al. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry , 2021, Journal for ImmunoTherapy of Cancer.
[17] R. Bjerkvig,et al. Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors , 2021, Neuro-oncology.
[18] F. Lang,et al. Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors , 2021, Journal of NeuroInterventional Surgery.
[19] M. Hidalgo,et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects , 2021, Journal for ImmunoTherapy of Cancer.
[20] M. Caligiuri,et al. An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma , 2021, Nature Communications.
[21] Jian Hu,et al. Glioblastoma Genetic Drivers Dictate the Function of Tumor-Associated Macrophages/Microglia and Responses to CSF1R Inhibition. , 2021, Neuro-oncology.
[22] J. Virga,et al. Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity , 2021, International journal of molecular sciences.
[23] M. Lamfers,et al. The Multifaceted Role of Macrophages in Oncolytic Virotherapy , 2021, Viruses.
[24] T. D. de Gruijl,et al. Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1 , 2021, Frontiers in Immunology.
[25] Xiao Liang,et al. Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy , 2021, Frontiers in Cell and Developmental Biology.
[26] M. Röcken,et al. Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma , 2021, Translational oncology.
[27] Atique U. Ahmed,et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. , 2021, The Lancet. Oncology.
[28] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[29] D. Aminin,et al. Macrophages as a “weapon” in anticancer cellular immunotherapy , 2021, The Kaohsiung journal of medical sciences.
[30] Jiong Cai,et al. Cytotoxic T lymphocyte‐associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells , 2021, International journal of cancer.
[31] M. Sanson,et al. SLIT2-ROBO signaling in tumor-associated microglia/macrophages drives glioblastoma immunosuppression and vascular dysmorphia , 2021, bioRxiv.
[32] J. Johnston,et al. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. , 2021, The New England journal of medicine.
[33] S. Reich-Zeliger,et al. P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression , 2021, Nature Communications.
[34] Fusheng Liu,et al. P4HA1 Down-Regulation Inhibits Glioma Invasiveness by Promoting M1 Microglia Polarization , 2021, OncoTargets and therapy.
[35] A. Heimberger,et al. FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. , 2021, Cancer letters.
[36] Anirban Ghosh,et al. Dichotomy in Growth and Invasion from Low- to High-Grade Glioma Cellular Variants , 2021, Cellular and Molecular Neurobiology.
[37] M. Borad,et al. Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. , 2021, JCO precision oncology.
[38] H. Fine,et al. Diffuse Glioma Heterogeneity and Its Therapeutic Implications. , 2021, Cancer discovery.
[39] D. Bartlett,et al. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity , 2021, Cancer Immunology, Immunotherapy.
[40] M. Ivan,et al. Clinical trials using oncolytic viral therapy to treat adult glioblastoma: a progress report. , 2021, Neurosurgical focus.
[41] J. Egen,et al. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment , 2021, Cancer Immunology, Immunotherapy.
[42] T. D. de Gruijl,et al. Oncolytic adenovirus ORCA-010 activates pro-inflammatory myeloid cells and facilitates T cell recruitment and activation by PD-1 blockade in melanoma. , 2021, Human gene therapy.
[43] L. Xue,et al. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer , 2021, Journal for ImmunoTherapy of Cancer.
[44] N. Hockstein,et al. Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer , 2020, Cell reports.
[45] R. Eftimie,et al. Oncolytic viral therapies and the delicate balance between virus-macrophage-tumour interactions: A mathematical approach. , 2020, Mathematical biosciences and engineering : MBE.
[46] Ting Zhang,et al. Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.
[47] A. Yang,et al. Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity , 2020, Molecular Cancer Therapeutics.
[48] Alexander P. Landry,et al. Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma , 2020, Scientific Reports.
[49] E. Shusta,et al. Blood–Brain Barrier Modulation to Improve Glioma Drug Delivery , 2020, Pharmaceutics.
[50] G. McFadden,et al. Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses , 2020, Biomedicines.
[51] Steven J. M. Jones,et al. Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression , 2020, Nature Communications.
[52] Á. Ayuso-Sacido,et al. Oncolytic Virotherapy in Glioma Tumors , 2020, International journal of molecular sciences.
[53] A. Iavarone,et al. ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages , 2020, Nature Communications.
[54] Fusheng Liu,et al. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas , 2020, Cell Death & Disease.
[55] H. Friedman,et al. Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.
[56] B. Becher,et al. Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes , 2020, Cell.
[57] A. Loskog,et al. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses , 2020, Frontiers in Immunology.
[58] H. Neufeld,et al. Oncolytic vesicular stomatitis viruses selectively target M2 macrophages. , 2020, Virus research.
[59] J. Luan,et al. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment , 2020, Frontiers in Immunology.
[60] S. Johnston,et al. M1-like macrophages are potent producers of anti-viral interferons and M1-associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations , 2020, EBioMedicine.
[61] L. Seymour,et al. Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion , 2020, Cancers.
[62] E. Chiocca,et al. Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene , 2020, Molecular therapy. Methods & clinical development.
[63] C. Weidong,et al. Macrophage M1/M2 polarization. , 2020, European journal of pharmacology.
[64] S. H. van der Burg,et al. Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses. , 2020, Trends in immunology.
[65] N. Xia,et al. Intratumoral Delivery of a PD-1–Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade , 2020, Cancer immunology research.
[66] J. Rich,et al. Glioblastoma Stem Cells: Driving Resilience through Chaos. , 2020, Trends in cancer.
[67] Xikun Zhou,et al. Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.
[68] R. Wilkinson,et al. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro , 2020, Cancer Immunology, Immunotherapy.
[69] J. Klode,et al. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain , 2020, Frontiers in Immunology.
[70] Yi Wu,et al. Embelin Promotes Oncolytic Vaccinia Virus-Mediated Antitumor Immunity Through Disruption of IL-6/STAT3 Signaling in Lymphoma , 2020, OncoTargets and therapy.
[71] Hsin-Ell Wang,et al. Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors , 2020, Journal of neuro-oncology.
[72] H. Keyvani,et al. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment , 2020, Virology Journal.
[73] N. Matsumura,et al. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment , 2020, British Journal of Cancer.
[74] Kaitai Zhang,et al. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity , 2020, Molecular therapy oncolytics.
[75] M. Essand,et al. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer , 2020, Cell Death & Disease.
[76] Junhua Wu,et al. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma , 2019, British Journal of Cancer.
[77] A. van Dam,et al. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment , 2019, Acta Neuropathologica Communications.
[78] L. Walsh,et al. Microenvironmental Heterogeneity in Brain Malignancies , 2019, Front. Immunol..
[79] A. Boissonnas,et al. Ontogeny of Tumor-Associated Macrophages , 2019, Front. Immunol..
[80] D. J. Doty,et al. Differential transcriptional profiles identify microglial- and macrophage-specific gene markers expressed during virus-induced neuroinflammation , 2019, Journal of Neuroinflammation.
[81] Atique U. Ahmed,et al. HIF-1α Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma , 2019, Cell reports.
[82] K. Bockhorst,et al. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966 , 2019, Molecular Cancer Therapeutics.
[83] Jiwu Wei,et al. Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma , 2019, Molecular therapy oncolytics.
[84] H. Nishikawa,et al. Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.
[85] Yuquan Wei,et al. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[86] Zhiwei Chen,et al. Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression , 2018, Oncoimmunology.
[87] Quadri,et al. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo , 2019 .
[88] J. Stewart,et al. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer. , 2019, The Journal of surgical research.
[89] J. Utikal,et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression , 2018, British Journal of Cancer.
[90] B. J. Van den Eynde,et al. Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism , 2018, Cancer Immunology, Immunotherapy.
[91] W. Goins,et al. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment , 2018, Molecular therapy oncolytics.
[92] A. Kleijn,et al. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment , 2018, Neuro-oncology.
[93] T. Luider,et al. Comparative proteomic analysis of cat eye syndrome critical region protein 1- function in tumor-associated macrophages and immune response regulation of glial tumors , 2018, Oncotarget.
[94] J. Kzhyshkowska,et al. Monocytes and Macrophages as Viral Targets and Reservoirs , 2018, International journal of molecular sciences.
[95] B. Nelson,et al. Oncolytic viruses as engineering platforms for combination immunotherapy , 2018, Nature Reviews Cancer.
[96] C. Bettegowda,et al. Current state of immunotherapy for glioblastoma , 2018, Nature Reviews Clinical Oncology.
[97] John H. Sampson,et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus , 2018, The New England journal of medicine.
[98] Q. Gao,et al. Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells , 2018, Clinical and Experimental Medicine.
[99] D. Meruelo,et al. Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity , 2018, Molecular therapy oncolytics.
[100] Hongwei Liang,et al. Arginase‐1 is neither constitutively expressed in nor required for myeloid‐derived suppressor cell‐mediated inhibition of T‐cell proliferation , 2018, European journal of immunology.
[101] K. Ishii,et al. Oncolytic Reovirus Inhibits Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in a TLR3-Dependent Manner , 2018, The Journal of Immunology.
[102] Min-jung Park,et al. Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice , 2018, Scientific Reports.
[103] K. Aldape,et al. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] Matija Snuderl,et al. Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis. , 2018, Biomaterials.
[105] Steffen Dettling,et al. When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma , 2018, International journal of molecular sciences.
[106] S. Hansen,et al. Tumour‐associated microglia/macrophages predict poor prognosis in high‐grade gliomas and correlate with an aggressive tumour subtype , 2018, Neuropathology and applied neurobiology.
[107] H. Frieboes,et al. Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment , 2018, Journal of Immunotherapy for Cancer.
[108] Leland S. Hu,et al. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data , 2018, Neuro-oncology.
[109] P. Rennie,et al. Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3. , 2018, Cancer research.
[110] Yun Xu,et al. EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment , 2017, Journal of Neuroinflammation.
[111] J. Markert,et al. Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002 , 2017, Molecular therapy oncolytics.
[112] A. Unterberg,et al. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[113] R. Martuza,et al. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. , 2017, Cancer cell.
[114] S. Gygi,et al. Quantitative Temporal in Vivo Proteomics Deciphers the Transition of Virus-Driven Myeloid Cells into M2 Macrophages , 2017, Journal of proteome research.
[115] Z. Guo,et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy , 2017, Nature Communications.
[116] B. Kamińska,et al. Immune microenvironment of gliomas , 2017, Laboratory Investigation.
[117] N. Ratner,et al. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation , 2017, Oncotarget.
[118] P. Lowenstein,et al. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[119] A. Szalay,et al. Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells , 2016, Journal of Translational Medicine.
[120] Atique U. Ahmed,et al. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. , 2016, Cancer research.
[121] J. Rojas,et al. Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy. , 2016, Cancer cell.
[122] T. Cripe,et al. Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe? , 2016, Biomedicines.
[123] Peter J. Murray,et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.
[124] J. R. de Sousa,et al. In situ expression of M2 macrophage subpopulation in leprosy skin lesions. , 2016, Acta tropica.
[125] I. Weissman,et al. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo , 2016, PloS one.
[126] M. Prados,et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. , 2016, Neuro-oncology.
[127] I. Melero,et al. Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) , 2016, Clinical Cancer Research.
[128] Ginu A. Thomas,et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. , 2016, JCI insight.
[129] Helmut Kettenmann,et al. The role of microglia and macrophages in glioma maintenance and progression , 2015, Nature Neuroscience.
[130] J. Merchan,et al. Targeting tumor vasculature through oncolytic virotherapy: recent advances , 2015, Oncolytic virotherapy.
[131] S. Rohn,et al. Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps , 2015, Journal of Translational Medicine.
[132] H. Wishart,et al. Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. , 2015, Neuro-oncology.
[133] Patrick W. Lee,et al. Newly Recruited CD11b+, GR-1+, Ly6Chigh Myeloid Cells Augment Tumor-Associated Immunosuppression Immediately following the Therapeutic Administration of Oncolytic Reovirus , 2015, The Journal of Immunology.
[134] M. Lesniak,et al. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy , 2015, Oncoimmunology.
[135] M. Caligiuri,et al. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment , 2015, Clinical Cancer Research.
[136] A. Garg,et al. Newcastle disease virotherapy induces long‐term survival and tumor‐specific immune memory in orthotopic glioma through the induction of immunogenic cell death , 2015, International journal of cancer.
[137] E. Lattime,et al. The Addition of Recombinant Vaccinia HER2/neu to Oncolytic Vaccinia-GMCSF Given into the Tumor Microenvironment Overcomes MDSC-Mediated Immune Escape and Systemic Anergy , 2015, Cancer Gene Therapy.
[138] William A. Flavahan,et al. Periostin Secreted by Glioblastoma Stem Cells Recruits M2 Tumor-associated Macrophages and Promotes Malignant Growth , 2014, Nature Cell Biology.
[139] M. Berger,et al. Survival and low-grade glioma: the emergence of genetic information. , 2015, Neurosurgical focus.
[140] M. Caligiuri,et al. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[141] B. Seliger,et al. Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity , 2014, Clinical Cancer Research.
[142] S. Gordon,et al. The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.
[143] P. Marcato,et al. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms , 2013, British Journal of Cancer.
[144] Y. Kaneda,et al. Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma. , 2013, Clinical immunology.
[145] David E. Anderson,et al. Tumor-Associated Macrophages in Glioma: Friend or Foe? , 2013, Journal of oncology.
[146] S. Singhal,et al. Myeloid derived suppressor cells , 2013, Oncoimmunology.
[147] Y. Nishiyama,et al. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models , 2013, International journal of cancer.
[148] P. Marcato,et al. Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[149] D. Begley,et al. Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[150] A. Cerwenka,et al. Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth , 2012, The Journal of Immunology.
[151] A. Hemminki,et al. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[152] Xiaopei Huang,et al. NK Cell Response to Vaccinia Virus Is Regulated by Myeloid-Derived Suppressor Cells , 2012, The Journal of Immunology.
[153] M. von Knebel Doeberitz,et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.
[154] J. Lišková,et al. Apoptosis and necrosis in vaccinia virus-infected HeLa G and BSC-40 cells. , 2011, Virus research.
[155] Fei Li,et al. Glioma-initiating cells: A predominant role in microglia/macrophages tropism to glioma , 2011, Journal of Neuroimmunology.
[156] Guangjian Huang,et al. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function , 2011, Scandinavian journal of gastroenterology.
[157] A. Heimberger,et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. , 2010, Neuro-oncology.
[158] R. Zinkernagel,et al. Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon‐I‐dependent manner in mice , 2010, Hepatology.
[159] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[160] F. Marincola,et al. The complex role of B7 molecules in tumor immunology. , 2008, Trends in molecular medicine.
[161] E. Chiocca,et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[162] D. Brat,et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. , 2007, Cancer research.
[163] T. Chou,et al. 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer , 2005, Journal of Gastrointestinal Surgery.
[164] M. Colombo,et al. The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.
[165] M. Caligiuri,et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses , 2006, Proceedings of the National Academy of Sciences.
[166] J. Markert,et al. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12 , 2005, Cancer Gene Therapy.
[167] H. Federoff,et al. Utilizing Tumor Hypoxia to Enhance Oncolytic Viral Therapy in Colorectal Metastases , 2004, Annals of surgery.
[168] M. Esteban,et al. Vaccinia virus induces apoptosis of infected macrophages. , 2002, The Journal of general virology.
[169] Kristi Kincaid,et al. M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.
[170] R. Martuza,et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.
[171] R. Singaravelu,et al. Oncolytic Viruses , 2021, Nature.